Instituto de Investigación Sanitaria Biobizkaia-ko ikertzaileekin lankidetzan egindako argitalpenak (56)

2023

  1. Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout

    Arthritis and Rheumatology, Vol. 75, Núm. 5, pp. 816-825

  2. Coronavirus Disease 2019 in Rheumatic Patientswith Inflammatory Disorders: A Descriptive Study from a High Infection Incidence Region of Northern Spain

    EUROPEAN JOURNAL OF RHEUMATOLOGY, Vol. 10, Núm. 4

  3. Mechanisms and rationale for uricase use in patients with gout

    Nature Reviews Rheumatology, Vol. 19, Núm. 10, pp. 640-649

2022

  1. Crystal-Associated Arthritis: Gout

    Synovial Fluid Analysis and the Evaluation of Patients with Arthritis (Springer International Publishing), pp. 91-100

  2. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

    Clinical Rheumatology, Vol. 41, Núm. 12, pp. 3817-3823

  3. Gout. What's up doc?

    Medicina Clinica, Vol. 158, Núm. 12, pp. 615-621

  4. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction

    Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658

  5. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study

    Arthritis Research and Therapy, Vol. 24, Núm. 1

2021

  1. Serum uric acid and mortality thresholds among men and women in the Irish health system: A cohort study

    European Journal of Internal Medicine, Vol. 84, pp. 46-55

2020

  1. High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?

    Rheumatology and Therapy, Vol. 7, Núm. 4, pp. 1011-1019

2019

  1. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600

  2. Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor Therapy

    Rheumatology and Therapy, Vol. 6, Núm. 1, pp. 101-108

2017

  1. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210

  2. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150

  3. Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015

    The Lancet, Vol. 390, Núm. 10091, pp. 231-266

  4. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid

    Joint Bone Spine, Vol. 84, Núm. 2, pp. 183-188

  5. Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard

    Arthritis and Rheumatology, Vol. 69, Núm. 2, pp. 429-438

2016

  1. Computational Lexical Analysis of the Language Commonly Used to Describe Gout

    Arthritis Care and Research, Vol. 68, Núm. 6, pp. 763-768

  2. Cost-effectiveness analysis of febuxostat in patients with gout in Spain

    Journal of Medical Economics, Vol. 19, Núm. 6, pp. 604-610

  3. Febuxostat for the chronic management of hyperuricemia in patients with gout

    Expert Review of Clinical Pharmacology, Vol. 9, Núm. 5, pp. 665-673